IPX237-B14-01: Evaluation of the Pharmacokinetics of Sublingual IPX237 in Healthy Volunteers

Trial Profile

IPX237-B14-01: Evaluation of the Pharmacokinetics of Sublingual IPX237 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jun 2016

At a glance

  • Drugs Esketamine (Primary) ; Esketamine (Primary)
  • Indications Depression
  • Focus Pharmacokinetics
  • Sponsors IMPAX Laboratories
  • Most Recent Events

    • 04 Jan 2015 Status changed from not yet recruiting to completed, according to Australian New Zealand Clinical Trials Registry record.
    • 05 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top